Mayuree Fuangthong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mayuree Fuangthong has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Sopapan Atichartpongkul
Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand
10 shared publicationsJuthamas Jaroensuk
Program in Applied Biological Sciences, Chulabhorn Graduate Institute, Bangkok, Thailand
7 shared publicationsSkorn Mongkolsuk
Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand; Center of Excellence on Environmental Health and Toxicology (EHT), OPS, MHESI, Bangkok, Thailand
7 shared publicationsMathuros Ruchirawat
Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand
5 shared publicationsJurairat Chittrakanwong
Program in Applied Biological Sciences, Chulabhorn Graduate Institute, Bangkok, Thailand
4 shared publicationsJutamaad Satayavivad
Program in Environmental Toxicology, Chulabhorn Graduate Institute, Bangkok, Thailand
4 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0288125
Development of an antigen detection test kit (Melioidosis-ATK) for point-of-care diagnosis of melioidosis
Melioidosis is a fatal infectious disease caused by the environmental bacterium Burkholderia pseudomallei . Although it is highly endemic in tropical regions, melioidosis remains underdiagnosed. The disease presents with diverse clinical manifestations, but diagnosis relies on time-consuming bacterial culture. Many patients with poor outcomes are referred from community hospitals, where culture facilities are unavailable. Early and accurate diagnosis is critical for timely treatment and improved outcomes. We developed an antigen detection test kit (Melioidosis-ATK) that targets the 6-deoxy-heptan capsular polysaccharide (CPS) of B. pseudomallei . The diagnostic performance of the assay was evaluated using 88 clinical samples, including blood culture broth (obtained from incubated blood culture bottles) ( N = 17), sputum ( N = 33), pus ( N = 17), urine ( N = 14), and other body fluids ( N = 7) from 88 patients with melioidosis, 204 samples from 195 patients with other bacterial infections, and 38 samples from 38 patients with negative blood culture. The assay demonstrated a limit of detection of 4.33 × 10³ CFU/mL for B. pseudomallei and 0.2 ng/mL for purified CPS. The Melioidosis-ATK demonstrated high diagnostic performance, with a sensitivity of 100% for blood culture broth, 84.9% for sputum, 88.2% for pus, 100% for urine, and 85.7% for other body fluids. The assay also exhibited a specificity of 100% across all sample types evaluated. The Kappa coefficient of agreement between the antigen test and culture for all clinical specimens ranged from 0.77 to 1.00. These findings suggest that the Melioidosis-ATK is a promising point-of-care (POC) diagnostic tool for use in rural hospitals, offering rapid, simple, equipment-free testing with high performance and has the potential to improve patient outcomes. IMPORTANCE: Melioidosis is a life-threatening but underrecognized infectious disease caused by Burkholderia pseudomallei , which predominantly occurs in regions with limited diagnostic capacity. A definitive diagnosis typically relies on bacterial culture, which is slow, technically demanding, and often unavailable in resource-constrained settings. To address this problem, we developed a rapid antigen detection assay (Melioidosis-ATK) that targets the 6-deoxy-heptan capsular polysaccharide (CPS) of B. pseudomallei and evaluated its performance using multiple clinical specimen types. The test demonstrated high sensitivity and specificity and can be performed as a point-of-care (POC) test. By enabling prompt diagnosis and timely initiation of effective therapy, this assay represents a practical tool to enhance clinical management and reduce disease-associated mortality in endemic regions.
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0288125
Open AccessDevelopment of an antigen detection test kit (Melioidosis-ATK) for point-of-care diagnosis of melioidosis
Melioidosis is a fatal infectious disease caused by the environmental bacterium Burkholderia pseudomallei . Although it is highly endemic in tropical regions, melioidosis remains underdiagnosed. The disease presents with diverse clinical manifestations, but diagnosis relies on time-consuming bacterial culture. Many patients with poor outcomes are referred from community hospitals, where culture facilities are unavailable. Early and accurate diagnosis is critical for timely treatment and improved outcomes. We developed an antigen detection test kit (Melioidosis-ATK) that targets the 6-deoxy-heptan capsular polysaccharide (CPS) of B. pseudomallei . The diagnostic performance of the assay was evaluated using 88 clinical samples, including blood culture broth (obtained from incubated blood culture bottles) ( N = 17), sputum ( N = 33), pus ( N = 17), urine ( N = 14), and other body fluids ( N = 7) from 88 patients with melioidosis, 204 samples from 195 patients with other bacterial infections, and 38 samples from 38 patients with negative blood culture. The assay demonstrated a limit of detection of 4.33 × 10³ CFU/mL for B. pseudomallei and 0.2 ng/mL for purified CPS. The Melioidosis-ATK demonstrated high diagnostic performance, with a sensitivity of 100% for blood culture broth, 84.9% for sputum, 88.2% for pus, 100% for urine, and 85.7% for other body fluids. The assay also exhibited a specificity of 100% across all sample types evaluated. The Kappa coefficient of agreement between the antigen test and culture for all clinical specimens ranged from 0.77 to 1.00. These findings suggest that the Melioidosis-ATK is a promising point-of-care (POC) diagnostic tool for use in rural hospitals, offering rapid, simple, equipment-free testing with high performance and has the potential to improve patient outcomes. IMPORTANCE: Melioidosis is a life-threatening but underrecognized infectious disease caused by Burkholderia pseudomallei , which predominantly occurs in regions with limited diagnostic capacity. A definitive diagnosis typically relies on bacterial culture, which is slow, technically demanding, and often unavailable in resource-constrained settings. To address this problem, we developed a rapid antigen detection assay (Melioidosis-ATK) that targets the 6-deoxy-heptan capsular polysaccharide (CPS) of B. pseudomallei and evaluated its performance using multiple clinical specimen types. The test demonstrated high sensitivity and specificity and can be performed as a point-of-care (POC) test. By enabling prompt diagnosis and timely initiation of effective therapy, this assay represents a practical tool to enhance clinical management and reduce disease-associated mortality in endemic regions.
- 2 August 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (19) , 169363
Corrigendum to “5-Methyluridine is Ubiquitous in Pseudomonas aeruginosa tRNA and Modulates Antimicrobial Resistance and Virulence” [J. Mol. Biol. 437(16) (2025) 169020]
- 2 August 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (19) , 169363
Corrigendum to “5-Methyluridine is Ubiquitous in Pseudomonas aeruginosa tRNA and Modulates Antimicrobial Resistance and Virulence” [J. Mol. Biol. 437(16) (2025) 169020]
- 6 March 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (16) , 169020
5-Methyluridine is Ubiquitous in Pseudomonas aeruginosa tRNA and Modulates Antimicrobial Resistance and Virulence
- 6 March 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (16) , 169020
5-Methyluridine is Ubiquitous in Pseudomonas aeruginosa tRNA and Modulates Antimicrobial Resistance and Virulence
- Open Access
- 3 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
16S rRNA methyltransferase KsgA contributes to oxidative stress and antibiotic resistance in Pseudomonas aeruginosa
Ribosomal RNA (rRNA) modifications are involved in multiple biological processes. KsgA is a 16S rRNA adenine dimethyltransferase that methylates at the adenines 1518 and 1519 (A1518/1519) positions, which are located near the ribosome decoding center. These methylations are conserved and important for ribosome biogenesis and protein translation. In this study, we demonstrated the absence of A1518/1519 methylation in the 16S rRNA of a Pseudomonas aeruginosa ksgA mutant. Biolog phenotypic microarrays were used to screen the phenotypes of the ksgA mutant against various antimicrobial agents. The loss of ksgA led to increased sensitivity to menadione, a superoxide generator, which was, at least in part, attributed to decreased in a superoxide dismutase (SOD) activity. Interestingly, the decrease in SOD activity in the ksgA mutant was linked to a decrease in the SodM protein levels, but not the sodM mRNA levels. Furthermore, the ksgA mutant strain exhibited sensitivity to hygromycin B and tylosin antibiotics. The tylosin-sensitive phenotype was correlated with decreased transcriptional levels of tufA, tufB, and tsf, which encode elongation factors. Additionally, the ksgA mutant showed resistance to kasugamycin. Collectively, these findings highlight the role of KsgA in oxidative stress responses and antibiotic sensitivity in P. aeruginosa.
- 3 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open Access16S rRNA methyltransferase KsgA contributes to oxidative stress and antibiotic resistance in Pseudomonas aeruginosa
Ribosomal RNA (rRNA) modifications are involved in multiple biological processes. KsgA is a 16S rRNA adenine dimethyltransferase that methylates at the adenines 1518 and 1519 (A1518/1519) positions, which are located near the ribosome decoding center. These methylations are conserved and important for ribosome biogenesis and protein translation. In this study, we demonstrated the absence of A1518/1519 methylation in the 16S rRNA of a Pseudomonas aeruginosa ksgA mutant. Biolog phenotypic microarrays were used to screen the phenotypes of the ksgA mutant against various antimicrobial agents. The loss of ksgA led to increased sensitivity to menadione, a superoxide generator, which was, at least in part, attributed to decreased in a superoxide dismutase (SOD) activity. Interestingly, the decrease in SOD activity in the ksgA mutant was linked to a decrease in the SodM protein levels, but not the sodM mRNA levels. Furthermore, the ksgA mutant strain exhibited sensitivity to hygromycin B and tylosin antibiotics. The tylosin-sensitive phenotype was correlated with decreased transcriptional levels of tufA, tufB, and tsf, which encode elongation factors. Additionally, the ksgA mutant showed resistance to kasugamycin. Collectively, these findings highlight the role of KsgA in oxidative stress responses and antibiotic sensitivity in P. aeruginosa.
- Open Access
- 28 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) presents a challenging diagnosis due to its nonspecific early clinical manifestations, often resulting in late-stage detection and high mortality. Diagnosing iCCA is further complicated by its limited accuracy, often necessitating multiple invasive procedures for precise identification. Despite carbohydrate antigen 19–9 (CA19-9) having been investigated and employed for iCCA diagnosis, it demonstrates modest diagnostic performance. Consequently, the identification of novel biomarkers with improved sensitivity and specificity remains an imperative yet formidable task. Autoantibodies, as early indicators of the immune response against cancer, offer a promising avenue for enhancing diagnostic accuracy. Our study aimed to identify non-invasive blood-based autoantibody biomarkers capable of distinguishing iCCA patients from healthy individuals (CTRs). We profiled autoantibodies in 26 serum samples (16 iCCAs and 10 CTRs) using protein microarrays containing 1622 functional proteins. Leveraging machine learning techniques, we identified a signature composed of three autoantibody biomarkers (NDE1, PYCR1, and VIM) in conjunction with CA19-9 for iCCA detection. This combined signature demonstrated superior diagnostic performance with an AUC of 96.9%, outperforming CA19-9 alone (AUC: 83.8%). These results suggest the potential of autoantibody biomarkers to develop a complementary non-invasive diagnostic utility for routine iCCA screening.
- 28 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessIdentification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) presents a challenging diagnosis due to its nonspecific early clinical manifestations, often resulting in late-stage detection and high mortality. Diagnosing iCCA is further complicated by its limited accuracy, often necessitating multiple invasive procedures for precise identification. Despite carbohydrate antigen 19–9 (CA19-9) having been investigated and employed for iCCA diagnosis, it demonstrates modest diagnostic performance. Consequently, the identification of novel biomarkers with improved sensitivity and specificity remains an imperative yet formidable task. Autoantibodies, as early indicators of the immune response against cancer, offer a promising avenue for enhancing diagnostic accuracy. Our study aimed to identify non-invasive blood-based autoantibody biomarkers capable of distinguishing iCCA patients from healthy individuals (CTRs). We profiled autoantibodies in 26 serum samples (16 iCCAs and 10 CTRs) using protein microarrays containing 1622 functional proteins. Leveraging machine learning techniques, we identified a signature composed of three autoantibody biomarkers (NDE1, PYCR1, and VIM) in conjunction with CA19-9 for iCCA detection. This combined signature demonstrated superior diagnostic performance with an AUC of 96.9%, outperforming CA19-9 alone (AUC: 83.8%). These results suggest the potential of autoantibody biomarkers to develop a complementary non-invasive diagnostic utility for routine iCCA screening.
- Open Access
Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool
At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the situation demands rapid development and production timelines of safe and effective vaccines for delivering life-saving medications quickly to patients. Typical biologics production relies on using the lengthy and arduous approach of stable single-cell clones. Here, we used an alternative approach, a stable cell pool that takes only weeks to generate compared to a stable single-cell clone that needs several months to complete. We employed the membrane, envelope, and highly immunogenic spike proteins of SARS-CoV-2 to produce virus-like particles (VLPs) using the HEK293-F cell line as a host system with an economical transfection reagent. The cell pool showed the stability of protein expression for more than one month. We demonstrated that the production of SARS-CoV-2 VLPs using this cell pool was scalable up to a stirred-tank 2 L bioreactor in fed-batch mode. The purified VLPs were properly assembled, and their size was consistent with the authentic virus. Our particles were functional as they specifically entered the cell that naturally expresses ACE-2. Notably, this work reports a practical and cost-effective manufacturing platform for scalable SARS-CoV-2 VLPs production and chromatographic purification.
Open AccessRapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool
At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the situation demands rapid development and production timelines of safe and effective vaccines for delivering life-saving medications quickly to patients. Typical biologics production relies on using the lengthy and arduous approach of stable single-cell clones. Here, we used an alternative approach, a stable cell pool that takes only weeks to generate compared to a stable single-cell clone that needs several months to complete. We employed the membrane, envelope, and highly immunogenic spike proteins of SARS-CoV-2 to produce virus-like particles (VLPs) using the HEK293-F cell line as a host system with an economical transfection reagent. The cell pool showed the stability of protein expression for more than one month. We demonstrated that the production of SARS-CoV-2 VLPs using this cell pool was scalable up to a stirred-tank 2 L bioreactor in fed-batch mode. The purified VLPs were properly assembled, and their size was consistent with the authentic virus. Our particles were functional as they specifically entered the cell that naturally expresses ACE-2. Notably, this work reports a practical and cost-effective manufacturing platform for scalable SARS-CoV-2 VLPs production and chromatographic purification.
- Open Access
- 16 January 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 1079710
Pseudomonas aeruginosa GidA modulates the expression of catalases at the posttranscriptional level and plays a role in virulence
Pseudomonas aeruginosa gidA, which encodes a putative tRNA-modifying enzyme, is associated with a variety of virulence phenotypes. Here, we demonstrated that P. aeruginosa gidA is responsible for the modifications of uridine in tRNAs in vivo. Loss of gidA was found to have no impact on the mRNA levels of katA and katB, but it decreased KatA and KatB protein levels, resulting in decreased total catalase activity and a hydrogen peroxide-sensitive phenotype. Furthermore, gidA was found to affect flagella-mediated motility and biofilm formation; and it was required for the full virulence of P. aeruginosa in both Caenorhabditis elegans and macrophage models. Together, these observations reveal the posttranscriptional impact of gidA on the oxidative stress response, highlight the complexity of catalase gene expression regulation, and further support the involvement of gidA in the virulence of P. aeruginosa.
- 16 January 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 1079710
Open AccessPseudomonas aeruginosa GidA modulates the expression of catalases at the posttranscriptional level and plays a role in virulence
Pseudomonas aeruginosa gidA, which encodes a putative tRNA-modifying enzyme, is associated with a variety of virulence phenotypes. Here, we demonstrated that P. aeruginosa gidA is responsible for the modifications of uridine in tRNAs in vivo. Loss of gidA was found to have no impact on the mRNA levels of katA and katB, but it decreased KatA and KatB protein levels, resulting in decreased total catalase activity and a hydrogen peroxide-sensitive phenotype. Furthermore, gidA was found to affect flagella-mediated motility and biofilm formation; and it was required for the full virulence of P. aeruginosa in both Caenorhabditis elegans and macrophage models. Together, these observations reveal the posttranscriptional impact of gidA on the oxidative stress response, highlight the complexity of catalase gene expression regulation, and further support the involvement of gidA in the virulence of P. aeruginosa.
- Open Access
- 10 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1063002
Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
Bispecific antibodies (BsAbs) form an exciting class of bio-therapeutics owing to their multispecificity. Although numerous formats have been developed, generation of hetero-tetrameric IgG1-like BsAbs having acceptable safety and pharmacokinetics profiles from a single cell culture system remains challenging due to the heterogeneous pairing between the four chains. Herein, we employed a structure-guided approach to engineer mutations in the constant domain interfaces (CH1-CL and CH3-CH3) of heavy and κ light chains to prevent heavy-light mispairing in the antigen binding fragment (Fab) region and heavy-heavy homodimerization in the Fc region. Transient co-transfection of mammalian cells with heavy and light chains of pre-existing antibodies carrying the engineered constant domains generates BsAbs with percentage purity ranging from 78% to 85%. The engineered BsAbs demonstrate simultaneous binding of both antigens, while retaining the thermal stability, Fc-mediated effector properties and FcRn binding properties of the parental antibodies. Importantly, since the variable domains were not modified, the mutations may enable BsAb formation from antibodies belonging to different germline origins and isotypes. The rationally designed mutations reported in this work could serve as a starting point for generating optimized solutions required for large scale production.
- 10 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1063002
Open AccessGeneration of bispecific antibodies by structure-guided redesign of IgG constant regions
Bispecific antibodies (BsAbs) form an exciting class of bio-therapeutics owing to their multispecificity. Although numerous formats have been developed, generation of hetero-tetrameric IgG1-like BsAbs having acceptable safety and pharmacokinetics profiles from a single cell culture system remains challenging due to the heterogeneous pairing between the four chains. Herein, we employed a structure-guided approach to engineer mutations in the constant domain interfaces (CH1-CL and CH3-CH3) of heavy and κ light chains to prevent heavy-light mispairing in the antigen binding fragment (Fab) region and heavy-heavy homodimerization in the Fc region. Transient co-transfection of mammalian cells with heavy and light chains of pre-existing antibodies carrying the engineered constant domains generates BsAbs with percentage purity ranging from 78% to 85%. The engineered BsAbs demonstrate simultaneous binding of both antigens, while retaining the thermal stability, Fc-mediated effector properties and FcRn binding properties of the parental antibodies. Importantly, since the variable domains were not modified, the mutations may enable BsAb formation from antibodies belonging to different germline origins and isotypes. The rationally designed mutations reported in this work could serve as a starting point for generating optimized solutions required for large scale production.
- Open Access
- 30 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interaction which underpins its mechanism of action remains unknown. In this study, we employed molecular docking combined with alanine scanning of epitope and paratope to predict a model of FGF23-Burosumab interaction. Then, we used the model to understand the species-species cross-reactivity of Burosumab and to reverse engineer mouse FGF23 with 'back to human' mutations to bind Burosumab. Finally, we redesigned the CDRs with two mutations to engineer an affinity enhanced variant of the antibody. Our study provides insights into the FGF23-Burosumab interaction and demonstrates that alanine-scanning coupled with molecular docking can be used to optimize antibody candidates (e.g., structure-guided affinity maturation) for therapeutic use.
- 30 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Open AccessPrediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interaction which underpins its mechanism of action remains unknown. In this study, we employed molecular docking combined with alanine scanning of epitope and paratope to predict a model of FGF23-Burosumab interaction. Then, we used the model to understand the species-species cross-reactivity of Burosumab and to reverse engineer mouse FGF23 with 'back to human' mutations to bind Burosumab. Finally, we redesigned the CDRs with two mutations to engineer an affinity enhanced variant of the antibody. Our study provides insights into the FGF23-Burosumab interaction and demonstrates that alanine-scanning coupled with molecular docking can be used to optimize antibody candidates (e.g., structure-guided affinity maturation) for therapeutic use.
- Open Access
- 16 May 2022
- Published by Springer Nature in Research Square
Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interaction which underpins its mechanism of action remains unknown. In this study, we first employed molecular docking combined with alanine scanning of epitope and paratope to predict a model of FGF23-Burosumab interaction. Then, we used the model to understand the species-species cross-reactivity of Burosumab and to reverse engineer mouse FGF23 with 'back to human' mutations to bind Burosumab. Finally, we redesigned the CDRs with two mutations to engineer an affinity enhanced variant of the antibody. Our study provides insights into the FGF23-Burosumab interaction and demonstrates that alanine-scanning coupled with molecular docking can be used to optimize antibody candidates (e.g., structure-guided affinity maturation) for therapeutic use.
- 16 May 2022
- Published by Springer Nature in Research Square
Open AccessPrediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interaction which underpins its mechanism of action remains unknown. In this study, we first employed molecular docking combined with alanine scanning of epitope and paratope to predict a model of FGF23-Burosumab interaction. Then, we used the model to understand the species-species cross-reactivity of Burosumab and to reverse engineer mouse FGF23 with 'back to human' mutations to bind Burosumab. Finally, we redesigned the CDRs with two mutations to engineer an affinity enhanced variant of the antibody. Our study provides insights into the FGF23-Burosumab interaction and demonstrates that alanine-scanning coupled with molecular docking can be used to optimize antibody candidates (e.g., structure-guided affinity maturation) for therapeutic use.